D-1771-2019 Class II Terminated
FDA drug recall D-1771-2019 was initiated by Infusion Options, Inc. on June 12, 2019 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated March 21, 2025). Affected quantity: N/A.
Recall Details
- Product Type
- Drugs
- Report Date
- August 21, 2019
- Initiation Date
- June 12, 2019
- Termination Date
- March 21, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- N/A
Product Description
Doxorubicin Liposomal 71 MG / 250 ML D5W IVPB; Doxorubicin Liposomal 66 MG/250 ML D5W, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233 Doxorubicin 16 MG/1000 ML NS IV WITH Vincristine 0.6 MG and Etoposide 78 MG Doxorubicin 16 MG/1000 ML NS IV WITH Vincristine 0.6 MG and Etoposide 78 MG Duplicate Doxorubicin 45 MG / 22.5 ML IVP SYRINGE
Reason for Recall
Lack of Assurance of Sterility
Distribution Pattern
NY only
Code Information
All lots within expiry